These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 32179964)

  • 1. [Biologicals and small molecules for rheumatoid arthritis].
    Blüml S
    Z Rheumatol; 2020 Apr; 79(3):223-231. PubMed ID: 32179964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis.
    Favalli EG; Matucci-Cerinic M; Szekanecz Z
    Autoimmun Rev; 2020 Jan; 19(1):102421. PubMed ID: 31733368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Louthrenoo W; Kasitanon N; Katchamart W; Aiewruengsurat D; Chevaisrakul P; Chiowchanwisawakit P; Dechanuwong P; Hanvivadhanakul P; Mahakkanukrauh A; Manavathongchai S; Muangchan C; Narongroeknawin P; Phumethum V; Siripaitoon B; Suesuwan A; Suwannaroj S; Uea-Areewongsa P; Ukritchon S; Asavatanabodee P; Koolvisoot A; Nanagara R; Totemchokchyakarn K; Nuntirooj K; Kitumnuaypong T
    Int J Rheum Dis; 2017 Sep; 20(9):1166-1184. PubMed ID: 28730640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.
    Tanaka Y
    Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi12-vi20. PubMed ID: 34951925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.
    Wong PKK; Bagga H; Barrett C; Chong G; Hanrahan P; Kodali T; Marabani M; Prince HM; Riordan J; Swarbrick P; White R; Young L
    Curr Rheumatol Rep; 2018 Sep; 20(10):64. PubMed ID: 30173305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment and management of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis.
    Mutlu MY; Tascilar K; Schett G
    Joint Bone Spine; 2023 Sep; 90(5):105578. PubMed ID: 37076093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for low disease activity and remission in rheumatoid arthritis patients treated with biological DMARDs.
    Wacharapornin P; Suwannalai P
    J Med Assoc Thai; 2014 Nov; 97(11):1157-63. PubMed ID: 25675680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.
    Doria A; Zavaglia D
    Clin Exp Rheumatol; 2019; 37(5):862-871. PubMed ID: 31376250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment algorithm for rheumatoid arthritis : According to the S2e guidelines 2018].
    Fiehn C; Krüger K
    Z Rheumatol; 2019 Aug; 78(6):529-539. PubMed ID: 31297605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune hallmarks of rheumatoid arthritis management: A brief review.
    Fonseca Peixoto R; Ewerton Maia Rodrigues C; Henrique de Sousa Palmeira P; Cézar Comberlang Queiroz Davis Dos Santos F; Keesen de Souza Lima T; de Sousa Braz A
    Cytokine; 2022 Oct; 158():156007. PubMed ID: 35985174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
    Gomez-Centeno A; Rubio-Romero E; Ovalles JG; Manrique-Arija S; Marsal-Barril S; Amarelo-Ramos J; Del Pino-Montes J; Muñoz-Fernández S; Bustabad S; Barbazán-Álvarez C
    Rheumatol Int; 2019 Dec; 39(12):2015-2024. PubMed ID: 31396685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
    Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
    Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical remission in rheumatoid arthritis and psoriatic arthritis.
    Lubrano E; Mesina F; Caporali R
    Clin Exp Rheumatol; 2018; 36(5):900-910. PubMed ID: 29600949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.
    Yoshikawa A; Yoshida S; Kimura Y; Tokai N; Fujiki Y; Kotani T; Matsumura Y; Takeuchi T; Makino S
    Mod Rheumatol; 2018 Mar; 28(2):227-234. PubMed ID: 28644744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in rheumatoid arthritis.
    Jones G; Nash P; Hall S
    Med J Aust; 2017 Mar; 206(5):221-224. PubMed ID: 28301793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?
    Cannella AC; O'Dell JR
    Curr Opin Rheumatol; 2003 May; 15(3):185-92. PubMed ID: 12707569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.